AbCellera | MedPath

AbCellera's ABCL575 Shows Promise for Atopic Dermatitis with Extended Half-Life in Preclinical Studies

12 days ago

• AbCellera's novel anti-OX40L monoclonal antibody ABCL575 demonstrates potent inhibition of inflammatory pathways in preclinical studies for moderate-to-severe atopic dermatitis treatment. • The drug candidate features a modified Fc domain providing a predicted human half-life exceeding 60 days, potentially enabling less frequent dosing compared to existing treatments. • ABCL575 targets OX40L, an upstream driver of the inflammatory cascade, which may provide broader inhibition of inflammatory pathways and more durable responses than currently approved biologics.

Sanofi Advances Respiratory Pipeline with Promising Amlitelimab Data in Heterogeneous Inflammatory Asthma

a month ago

• Sanofi's amlitelimab demonstrated clinically meaningful efficacy in heterogeneous inflammatory asthma, showing over 70% reduction in exacerbations in patients with specific biomarkers at week 60 of the TIDE-Asthma phase 2 study. • The company is expanding its respiratory portfolio with lunsekimig now targeting chronic rhinosinusitis and COPD alongside asthma, with phase 2 readouts anticipated in 2026. • Itepekimab, developed in partnership with Regeneron, is broadening its clinical program beyond COPD into chronic rhinosinusitis, with phase 3 readouts in COPD expected in H2 2025.

BriaCell to Present Pivotal Breast Cancer Immunotherapy Data at AACR 2025

2 months ago

• BriaCell Therapeutics will present data from three clinical studies at the 2025 AACR Annual Meeting, including results from its pivotal Phase 3 trial of Bria-IMT in metastatic breast cancer. • The presentations will showcase survival outcomes from a randomized Phase 2 trial of Bria-IMT, an allogeneic whole cell cancer vaccine, potentially offering new treatment options for advanced breast cancer patients. • BriaCell's novel immunotherapy platform Bria-OTS+ will also be featured, highlighting the company's expanding cancer immunotherapy portfolio and innovative approaches to inducing anti-cancer immunity.

Recursion-Exscientia Merger Signals New Era in AI-Driven Drug Discovery

3 months ago

• Recursion Pharmaceuticals and Exscientia have completed a landmark $700 million merger, marking the largest AI-focused life sciences deal to date and combining complementary capabilities in biological and chemical AI platforms. • The merged entity now boasts 10 programs in development and significant partnerships with pharmaceutical giants Sanofi and Roche, with their most advanced program targeting cerebral cavernous malformation in Phase 2. • Industry experts predict this merger will catalyze more AI-focused acquisitions in pharma, as companies seek to fully integrate artificial intelligence into traditional drug development processes.

Predictive Oncology Secures New Financing Through At-Market Direct Offering

3 months ago

• Predictive Oncology has launched a registered direct offering priced at-market under Nasdaq rules, demonstrating its efforts to strengthen its financial position for future operations. • The company plans to utilize the proceeds to support its ongoing operations and strategic initiatives in oncology-focused predictive technology development. • This financing move reflects Predictive Oncology's proactive approach to capital management while maintaining compliance with Nasdaq marketplace requirements.

AbbVie's Immunology Portfolio Shows Strong Growth Potential Despite Emraclidine Setback

4 months ago

• AbbVie faces a $3.5 billion impairment charge following emraclidine's Phase 2 trial failures, but maintains potential for its development as an adjunctive treatment. • The company's immunology franchise demonstrates resilience, projecting 2% growth in 2024 despite Humira's loss of exclusivity, with acceleration to 7% growth in 2025. • Goldman Sachs raises AbbVie's price target to $208, citing strong performance of Skyrizi and Rinvoq in immunology markets.

FDA Approvals and Clinical Trials: A Look into the Latest Pharmaceutical Developments

4 months ago

The pharmaceutical sector has seen significant advancements with FDA approvals for new treatments and the initiation of clinical trials for innovative therapies. Notably, Eli Lilly's Omvoh has been approved for Crohn's disease, and Johnson & Johnson is advancing its TAR-200 for bladder cancer treatment. These developments underscore the industry's commitment to addressing unmet medical needs through research and innovation.

JP Morgan 2025: AbbVie's Strategy with Skyrizi and Rinvoq to Compensate for Humira's Decline

4 months ago

AbbVie is focusing on Skyrizi and Rinvoq to offset the impact of Humira's patent expiration. The company also highlights the success of tavapadon in Parkinson’s disease trials and new partnerships for drug development.

AbbVie's Skyrizi and Rinvoq Gain Market Share as Company Navigates Post-Humira Landscape

4 months ago

• AbbVie reports significant market penetration for Skyrizi and Rinvoq in IBD indications, capturing approximately 50% market share in Crohn's disease and ulcerative colitis treatment spaces. • Despite Humira's 32% sales decline following biosimilar entry in 2023, only 20% of patients have transitioned to biosimilars, with many physicians preferring AbbVie's newer immunology drugs. • The company is exploring combination therapy potential, particularly investigating TL1A therapies with Skyrizi, while also advancing its neurology pipeline with tavapadon showing promising Phase III results in Parkinson's disease.

4DMT Prioritizes 4D-150 and 4D-710, Extends Cash Runway into 2028

4 months ago

• 4DMT is focusing its pipeline on 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis, leveraging their strong clinical proof of concept. • Phase 3 trials (4FRONT-1 and 4FRONT-2) for 4D-150 in wet AMD are set to begin in Q1 and Q3 2025, respectively, with topline data expected in H2 2027. • The company's cash runway has been extended to 2028, supported by $506M in cash reserves and strategic resource allocation. • 4DMT will discontinue development of early-stage programs like 4D-110 for choroideremia and 4D-125 for X-linked retinitis pigmentosa.

FDA Revokes Emergency Use Authorizations for Four COVID-19 Monoclonal Antibody Products

5 months ago

• The FDA has revoked the Emergency Use Authorizations (EUAs) for four monoclonal antibody products used in the U.S. government's COVID-19 response. • The revoked EUAs include treatments from Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron Pharmaceuticals due to the rise of resistant SARS-CoV-2 variants. • These monoclonal antibody products have not been authorized for patient administration for over a year because of ineffective against current variants. • Healthcare facilities will receive instructions from the sponsors for the return and disposal of the revoked products.

DeepMind Launches Isomorphic Labs to Transform Drug Discovery Through AI Innovation

4 years ago

• Alphabet's DeepMind has established Isomorphic Labs, a standalone AI-driven drug discovery company that will leverage the breakthrough AlphaFold protein structure prediction technology. • The new venture will be led by DeepMind founder Demis Hassabis and aims to revolutionize drug discovery by implementing an AI-first approach while building partnerships with pharmaceutical companies. • Isomorphic Labs will utilize DeepMind's AlphaFold2 database, which has successfully mapped nearly all human proteins and achieved sufficient precision for drug design in one-third of its protein models.